Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340662 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT03340662 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 81 participants.
The verdict
NCT03340662, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a phase 1 open-label 4-part study to evaluate the effect of food, cytochrome P450 inhibition and induction on the pharmacokinetics of CC 122 in healthy adult subjects. Approximately 81 subjects will be enrolled. There will be approximately 24 subjects in Part 1 and approximately 19 subjects in Parts 2, 3, and 4, respectively. Subjects may participate in 1 part only.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG Fluvoxamine
- DRUG CC-122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2018-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340662
The ClinicalTrials.gov registry entry for NCT03340662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rifampin is the first listed.
NCT03340662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03340662 about?
NCT03340662 is a clinical study titled "Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122". This is a phase 1 open-label 4-part study to evaluate the effect of food, cytochrome P450 inhibition and induction on the pharmacokinetics of CC 122 in healthy adult subjects. Approximately 81 subjects will be enrolled. There will be approximately 24 subjects in Part 1 and approximately 19 subjects ...
What is the current status of trial NCT03340662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2017-11-09. Estimated completion is 2018-01-27.
What interventions are being tested in trial NCT03340662?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), Fluvoxamine (DRUG), CC-122 (DRUG).
Who is sponsoring clinical trial NCT03340662?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.